Dasatinib

製品コードS1021 別名:BMS-354825

Dasatinib化学構造

分子量(MW):488.01

Dasatinibは一種の新たで、有効な多ターゲット阻害剤で、無細胞試験でAbl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。

サイズ 価格 在庫  
USD 176 あり
USD 185 あり
USD 466 あり

文献中の引用(62)

カスタマーフィードバック(10)

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

製品安全説明書

Src阻害剤の選択性比較

生物活性

製品説明 Dasatinibは一種の新たで、有効な多ターゲット阻害剤で、無細胞試験でAbl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。
ターゲット
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外試験

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NYrocpoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr1S|dvPzJiaB?= NVG5OIV6TE2VTx?= NWHwZ29DUUN3ME2wMlAxODB5IN88US=> MXexO|k2PjB6MB?=
K562 M1\ZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPJOpg4OiCq NESxbmpFVVOR M3zOOWlEPTB;MD6wNFEh|ryP NFvPTIIyPzl3NkC4NC=>
M07e NULNWVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp NV7yUGdXTE2VTx?= NHjwbGxKSzVyPUCuNFAyOiEQvF2= MX6xO|k2PjB6MB?=
ALL3 MV7DfZRwfG:6aXOgRZN{[Xl? MYSwMlHPxE1? M1SxR|czKGh? NHjp[5pFVVOR M{\Gb2lEPTB;MD6wNFA1KM7:TR?= MkKyNVk5QDl3NEC=
CML NGj4e5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0OlIxKG2rbh?= NV;FTok6TE2VTx?= M3fjXWlEPTB;MD6wNFEh|ryP MlvINVkzOTlyMU[=
BA/F3 NF22ZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NkBp NETlR21FVVOR NX\KXlh3UUN3ME22MlU5QSEQvF2= MXWyN|A5QDZ2NB?=
BA/F3 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XlOlczKGh? NXvWWGpWTE2VTx?= MXzJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= M16wUFI{ODh6NkS0
BA/F3 NX7rOVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfjO|IhcA>? MWHEUXNQ MVXJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO NIXGUZEzOzB6OE[0OC=>
BA/F3 NXi2cYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DTXlczKGh? M1LDO2ROW09? MWXJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? MWKyN|A5QDZ2NB?=
BA/F3 M3m2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z1OFczKGh? M37Jd2ROW09? MoniTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? M1nmcVI{OzBzN{Cz
BA/F3 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjyVJdTPzJiaB?= NXzQV4lwTE2VTx?= MmDDTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? MV[yN|MxOTdyMx?=
BA/F3 M4H0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXGO|IhcA>? MnnoSG1UVw>? MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NF3UcJMzOzNyMUewNy=>
BA/F3 M2fVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\FRlczKGh? NH3ie|BFVVOR NI\KPYtKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP MUKyN|MxOTdyMx?=
BA/F3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WxVlczKGh? NGnTdXhFVVOR Mn\UTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? NVr1NXNHOjN|MEG3NFM>
BA/F3 NWTRNVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW3NkBp MVnEUXNQ M2HnT2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO Mn\WNlM{ODF5MEO=
BA/F3 NG\UNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWyO|IhcA>? M4jTZWROW09? MXfJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NX7HNndMOjN|MEG3NFM>
BA/F3 NFKySWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jqdlczKGh? NUHEb|h2TE2VTx?= M3zXUWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO NV3rVXU{OjN|MEG3NFM>
BA/F3 NX7FdHZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP4PVdyPzJiaB?= MUDEUXNQ MmHtTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP M4SyNlI{OzBzN{Cz
T cell MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp Ml3zSG1UVw>? NY\aTYxxUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? NF\sbJoyPzF3NEWxNi=>
WiDr MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PId|czKGh? NW\Nbo81TE2VTx?= Mn7MTWM2OD1yLkC1NkDPxE1? M4PD[VE2PjF3NUGy
PC3 NX7TZlJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T4PFczKGh? NX35T2dXTE2VTx?= NYHBNHdSUUN3ME2wMlAxQTRizszN NEO1NnkyPTZzNUWxNi=>
MDA-MB-231 M2f4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS3O|IhcA>? NH\VVmpFVVOR M1LXemlEPTB;MD6wNVIh|ryP NEjPXZYyPTZzNUWxNi=>
Hs578T NX7EOlVDS3m2b4TvfIlkKEG|c3H5 NH7KSY04OiCq MVnEUXNQ NH\XOnNIUTVyPUCuNFMh|ryP NEmxTIozPDBzNUOyOy=>
HMEC M4jl[GN6fG:2b4jpZ{BCe3OjeR?= Mn75O|IhcA>? MnvvSG1UVw>? MXXHTVUxRTFwODFOwG0> MmrONlQxOTV|Mke=
DU145 MYPDfZRwfG:6aXOgRZN{[Xl? Mli1O|IhcA>? MWLEUXNQ MlLpS2k2OD1yLkG2JO69VQ>? NUnicGNtOjRyMUWzNlc>
U251 M1z4bmN6fG:2b4jpZ{BCe3OjeR?= NX\zdJdDPzJiaB?= M2TnUWROW09? NXHp[|U2T0l3ME2yMlgyKM7:TR?= M4f1[FI1ODF3M{K3
NCI60 MonrR5l1d3SxeHnjJGF{e2G7 M3TwNFczKGh? MofESG1UVw>? NU\NXnE1T0l3ME21Mlch|ryP MUSyOFAyPTN{Nx?=
MALME-3M NEG1e2NEgXSxdH;4bYMhSXO|YYm= MUS3NkBp NYn5SZlJTE2VTx?= MoOzS2k2OD14Lk[xJO69VQ>? MXyyOFAyPTN{Nx?=
KM12 NXPPZZBrS3m2b4TvfIlkKEG|c3H5 MmDJO|IhcA>? M2XafWROW09? MkHBS2k2OD15LkS0JO69VQ>? NY\HSZR1OjRyMUWzNlc>
SW620 NUfkNWFNS3m2b4TvfIlkKEG|c3H5 MVG3NkBp MlTPSG1UVw>? MWnHTVUxRThwNEOg{txO MUWyOFAyPTN{Nx?=
RXF 393NL MY\DfZRwfG:6aXOgRZN{[Xl? MV60JIRigXN? M1;BV2ROW09? NGK4cWlKSzVyPUCuNFIyPyEQvF2= MkXINlMzPTNyN{S=
LXFA 983L MX7DfZRwfG:6aXOgRZN{[Xl? MUG0JIRigXN? MnTmSG1UVw>? NYHjfmpXUUN3ME2wMlA2PjVizszN MWKyN|I2OzB5NB?=
PRXF DU145 MYrDfZRwfG:6aXOgRZN{[Xl? MWq0JIRigXN? M3rLZ2ROW09? NIru[VlKSzVyPUCuNFYzOyEQvF2= M3iwfFI{OjV|MEe0
PAXF 1657L MoX4R5l1d3SxeHnjJGF{e2G7 MWq0JIRigXN? NYnHZVRRTE2VTx?= NFviPIFKSzVyPUCuNVIyKM7:TR?= NFntdm0zOzJ3M{C3OC=>
CXF 1103L MnHQR5l1d3SxeHnjJGF{e2G7 MkDmOEBl[Xm| NUTzO|RtTE2VTx?= NHjablhKSzVyPUSuN|Yh|ryP M{nPXlI{OjV|MEe0
GXF251L NGXZOGJEgXSxdH;4bYMhSXO|YYm= NYPkPGJJPCCmYYnz M2PlOmROW09? MnLGTWM2OD1{LkK1JO69VQ>? M4\reFI{OjV|MEe0
NCI-H23 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnznO|IhcA>? NIPwZoNFVVOR MXjJR|UxRTJwMkeg{txO NXPaV2ZVOjN3MkGwNlA>
HCT116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp NEPONYFFVVOR MWnJR|UxRTJwMzFOwG0> NILxWJczOzV{MUCyNC=>
MCF7 M2jLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXaeGNuPzJiaB?= NWDK[pFVTE2VTx?= MUfJR|UxRTJwNUeg{txO NVzWRZFkOjN3MkGwNlA>
NCI-H460 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi5O|IhcA>? MkPPSG1UVw>? NXXrfFBWUUN3ME24Mlk6KM7:TR?= MWiyN|UzOTB{MB?=
DLD1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:1RYs4OiCq NF\IZmZFVVOR M4fmVGlEPTB;ND62JO69VQ>? M171WVI{PTZ5OU[w
NCI-H661 M3nSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC3NkBp NY\UV2JvTE2VTx?= NHjKVIhKSzVyPUeuPEDPxE1? MoDSNlM2Pjd7NkC=
A549 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG3NkBp NFm0cG9FVVOR NV;NUZB6UUN3ME24MlIh|ryP NH;RbZkzOzV4N{m2NC=>
U937 NVfIU2E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HsNFczKGh? NID6T49FVVOR M{XGd2lEPTB;MUKuNkDPxE1? MViyN|U3Pzl4MB?=
HEK293 M4PFSmZ2dmO2aX;uJGF{e2G7 NX;vS3I2OTEEoN88US=> NGTNWGZFVVOR MVzJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= MYiyNlc4ODZzMB?=
HUVEC M3\5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuyNE4yPcLizszN NHPVT5k4OiCq MWTEUXNQ NGH0WVlKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> NGT3co8zOjh3M{m5Ny=>
HUVEC M2O0OmZ2dmO2aX;uJGF{e2G7 NWO5VJN{OTYEoN88US=> MYi3NkBp NX3tdIQ4TE2VTx?= MVPJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> MUSyNlg2Ozl7Mx?=
Plasmodium falciparum MoLaSpVv[3Srb36gRZN{[Xl? NV\VXZo2OTEEoN88US=> MXuxOUBucW5? MYLEUXNQ NWjYTnJ4UW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP NIfsOZgzPDV3MEOzNC=>
PC3 MXjGeY5kfGmxbjDBd5NigQ>? MnjmNE4yKM7:TR?= NGnD[XI2KGh? MXzEUXNQ NEnHNpVKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= MlXVNVk1PjJ7N{W=
DU145 NFS1enFHfW6ldHnvckBCe3OjeR?= M3PVdlAvOSEQvF2= M{TCVFUhcA>? MULEUXNQ NEGxWpJKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> MWqxPVQ3Ojl5NR?=
PC3 MU\LbY5ie2ViQYPzZZk> MXiwMlEh|ryP Mnz1OUBp NIWyXW1FVVOR MVvJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P NV7Oeo05OTl2NkK5O|U>
DU145 M2PTSGtqdmG|ZTDBd5NigQ>? MlX5NE4yKM7:TR?= M{XUVFUhcA>? MnjZSG1UVw>? MkfhTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MnLXNVk1PjJ7N{W=
PC3 NXj0NXFVU2mwYYPlJGF{e2G7 NWTkbIpEOC5zIN88US=> MU[1JIg> MmDUSG1UVw>? NYnFc3AyUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P MV:xPVQ3Ojl5NR?=
DU145 MYDLbY5ie2ViQYPzZZk> NIns[G8xNjFizszN MXe1JIg> NGPZOWlFVVOR NH\NPItKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NVzWNGJJOTl2NkK5O|U>
Huh7 MUXBcpRqfmm{YXygRZN{[Xl? NW\wRoNKOi53IN88US=> NH7FZYE1KGSjeYO= NYDHeYZyTE2VTx?= MUnJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? NFXhcYkyPzN4ME[3Oi=>
C6/36 Mnr3RY51cX[rcnHsJGF{e2G7 NVW4cJJOOi53IN88US=> NEXpVlI1KGSjeYO= MmnBSG1UVw>? MUnJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO NXnJVXlGOTd|NkC2O|Y>
U937 M2f3eGZ2dmO2aX;uJGF{e2G7 M3XxTVEh|ryP MVOxJIg> NXL5V3FZTE2VTx?= MVHS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? NXe4bmFWOTd4OESwPVk>
U937 MVjGeY5kfGmxbjDBd5NigQ>? MXuxJO69VQ>? MU[xJIg> NVXlRYZjTE2VTx?= NFS3PJJT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MXixO|Y5PDB7OR?=
murine mast cell MmPkSpVv[3Srb36gRZN{[Xl? NFfNcZoyKM7:TR?= M{PIe|I1KGh? NXrJeI1KTE2VTx?= NIn1OIFKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= NGHOXmUyPzZ6NEC5PS=>
BV-173 NHX5XnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC3flFHUUN3ME2wMlAxODByMEGwPUDPxE1? NY\nTYhUW0GQR1XS
K-562 M3jo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrEeYxSUUN3ME2wMlAxODByMEK2OkDPxE1? NXTle|NuW0GQR1XS
BL-70 M2PsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMECwNFAxQDJ{IN88US=> MVHTRW5ITVJ?
EM-2 NF7oOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;BW|lKSzVyPUCuNFAxODBzMEig{txO MUfTRW5ITVJ?
LAMA-84 NXvmN4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMECwNFA{OjFizszN NYS0WXN1W0GQR1XS
MEG-01 NGH1WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzTTWM2OD1yLkCwNFAxQThizszN M2DaXXNCVkeHUh?=
EoL-1-cell Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX2SYd4UUN3ME2wMlAxODBzM{Gg{txO MWfTRW5ITVJ?
CTV-1 NX3lZotRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMECwNFQxPCEQvF2= MWfTRW5ITVJ?
TE-15 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMEC1PFkh|ryP MXXTRW5ITVJ?
NOS-1 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rwVmlEPTB;MD6wNFYyOyEQvF2= M1vmXXNCVkeHUh?=
D-336MG M4LncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITzSIdKSzVyPUCuNFA3OyEQvF2= NWrROnQ3W0GQR1XS
LB1047-RCC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEC5PFkh|ryP NFrQfZZUSU6JRWK=
LB996-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEC5PVEh|ryP NFz3NlNUSU6JRWK=
SW982 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\RZoxKSzVyPUCuNFEyOTVizszN M2eybHNCVkeHUh?=
TK10 NGT6VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXTeZhKSzVyPUCuNFEyPzRizszN NETtVI5USU6JRWK=
A704 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLRZWRKSzVyPUCuNFE1QTFizszN M2jrR3NCVkeHUh?=
TE-8 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{exSmlEPTB;MD6wNVU4PiEQvF2= MYnTRW5ITVJ?
DOHH-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;x[4RKSzVyPUCuNFE4OTlizszN MYHTRW5ITVJ?
HOP-62 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHodIdKSzVyPUCuNFE5OzRizszN NHWyPItUSU6JRWK=
TE-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rtTWlEPTB;MD6wNVg3OSEQvF2= NWD1RXdLW0GQR1XS
KGN M3vC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEG5OFIh|ryP MULTRW5ITVJ?
NCI-H1648 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn25TWM2OD1yLkCyNFEyKM7:TR?= NXLBcJVHW0GQR1XS
OS-RC-2 NHeyWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEKwN{DPxE1? NInIN4xUSU6JRWK=
GB-1 NETLZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTsTWM2OD1yLkCyNVU4KM7:TR?= Ml6zV2FPT0WU
RXF393 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXkTWM2OD1yLkCyN|U4KM7:TR?= MVrTRW5ITVJ?
LC-2-ad MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zhdGlEPTB;MD6wNlU5PiEQvF2= M1Xw[HNCVkeHUh?=
KS-1 NGDDUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\XTWM2OD1yLkCyO|Mh|ryP Mki2V2FPT0WU
ETK-1 NWrRRVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Dye2lEPTB;MD6wNlg{OiEQvF2= NFLSZZhUSU6JRWK=
SW954 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm3TWM2OD1yLkCyPVI4KM7:TR?= MXjTRW5ITVJ?
Becker Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXsUZpKSzVyPUCuNFMxODNizszN Mm\hV2FPT0WU
MZ1-PC M{Swe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P4RmlEPTB;MD6wN|EyQSEQvF2= NX;6O4hmW0GQR1XS
ES6 NWftPFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XhWmlEPTB;MD6wN|E6OyEQvF2= NGS1NYZUSU6JRWK=
KURAMOCHI MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH2bm9KSzVyPUCuNFM1QDdizszN MmPEV2FPT0WU
CGTH-W-1 M3;0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHz[3Z5UUN3ME2wMlA{PTR6IN88US=> MoXrV2FPT0WU
VA-ES-BJ MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvv[IxxUUN3ME2wMlA{QTB{IN88US=> MXnTRW5ITVJ?
LXF-289 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLEUnJ{UUN3ME2wMlA{QTV4IN88US=> NH\WSm9USU6JRWK=
MPP-89 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfVUHlKSzVyPUCuNFQxPDlizszN NULvblFxW0GQR1XS
SW872 M4XJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnvZ2JIUUN3ME2wMlA1OTZzIN88US=> NVzve5dEW0GQR1XS
SNB75 NYrMN|NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3TTWM2OD1yLkC0OFM2KM7:TR?= M3jBOXNCVkeHUh?=
PSN1 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3GWlNKSzVyPUCuNFQ1PzRizszN NFL2dVdUSU6JRWK=
LB831-BLC NGD6eZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mSmJKSzVyPUCuNFQ3ODlizszN MV;TRW5ITVJ?
MFH-ino MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMES3NlQh|ryP NEjMd|BUSU6JRWK=
TGBC24TKB NFG1VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTRUFBHUUN3ME2wMlA1PzZzIN88US=> NHrQXG1USU6JRWK=
A388 NF;RXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEWwPVUh|ryP NXKzd2x{W0GQR1XS
BB30-HNC NWjIbnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEW0N|ch|ryP NV3ubm9PW0GQR1XS
GI-ME-N M4XScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7mcnBKSzVyPUCuNFYyOThizszN MmDoV2FPT0WU
TGBC1TKB NGnM[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwME[xOlQh|ryP NWHsRldnW0GQR1XS
TE-10 M2[4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwME[zOVch|ryP M2W3b3NCVkeHUh?=
A498 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKzbpo6UUN3ME2wMlA4Ojh2IN88US=> NX\kSXZXW0GQR1XS
TE-11 NYfhVoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vEOGlEPTB;MD6wO|g2QCEQvF2= M2rQPHNCVkeHUh?=
BB65-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTmcYdKSzVyPUCuNFgzOjdizszN NVK0Nm82W0GQR1XS
C2BBe1 NWjoeYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfmdHppUUN3ME2wMlA5OzB6IN88US=> M{LPPXNCVkeHUh?=
NCI-H747 NXzkb3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEizOlIh|ryP NEfBOXRUSU6JRWK=
IST-MES1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfaRnZKSzVyPUCuNFg2PTJizszN MX;TRW5ITVJ?
KALS-1 NVPuNppWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7HV5dKSzVyPUCuNFk1QSEQvF2= MkTlV2FPT0WU
GCIY Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPlTWM2OD1yLkC5OlU3KM7:TR?= M3zOSXNCVkeHUh?=
RL95-2 NFKwUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnqO5F[UUN3ME2wMlExOzhizszN M33vO3NCVkeHUh?=
TE-1 NILV[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HJZWlEPTB;MD6xNFU1KM7:TR?= MUDTRW5ITVJ?
NCI-H1355 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMUGwNlgh|ryP M3XsN3NCVkeHUh?=
SW962 NFLrR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUGyPVIh|ryP MoHQV2FPT0WU
KLE NITTWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL2TWM2OD1yLkGxN|E4KM7:TR?= Ml7KV2FPT0WU
MC116 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrBW2FKSzVyPUCuNVE1OSEQvF2= M{jEUHNCVkeHUh?=
NMC-G1 NHO0[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUG2NFYh|ryP NEfMT5JUSU6JRWK=
KU812 M3;vbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjxUFRXUUN3ME2wMlEyQDh|IN88US=> MYjTRW5ITVJ?
COLO-829 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHIbWJ3UUN3ME2wMlEzOjF|IN88US=> MUPTRW5ITVJ?
NTERA-S-cl-D1 M1m1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH5PGdKSzVyPUCuNVIzQDNizszN NFvENXpUSU6JRWK=
IST-MEL1 M3nv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm4XmxKSzVyPUCuNVM1PSEQvF2= M4jD[HNCVkeHUh?=
MLMA M{m2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7KTWM2OD1yLkG0NFMzKM7:TR?= M1jwNnNCVkeHUh?=
LS-123 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2exZWlEPTB;MD6xOFA3PCEQvF2= M1\EOHNCVkeHUh?=
LB2518-MEL M1\1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Bd2lEPTB;MD6xOFE3OiEQvF2= M3\tb3NCVkeHUh?=
NB69 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC2TWM2OD1yLkG0OFM3KM7:TR?= MkTjV2FPT0WU
8-MG-BA MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETIOmNKSzVyPUCuNVU1PThizszN M{X3c3NCVkeHUh?=
K5 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMU[0PFkh|ryP M1nBS3NCVkeHUh?=
KINGS-1 NGDwO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy3WY5oUUN3ME2wMlE3PjZ4IN88US=> MlezV2FPT0WU
SF268 NHLp[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPnTWM2OD1yLkG3OFA1KM7:TR?= MmXRV2FPT0WU
PF-382 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i0WmlEPTB;MD6xO|Y4QCEQvF2= NIO3NmNUSU6JRWK=
SH-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP1TWM2OD1yLkG4OFE{KM7:TR?= NUmx[2tKW0GQR1XS
NALM-6 NXjRdIJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX5ZpE5UUN3ME2wMlE6Ojl3IN88US=> NWDwdXFnW0GQR1XS
CP66-MEL M{j4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL2[IZ7UUN3ME2wMlE6PTNzIN88US=> M3\ObXNCVkeHUh?=
697 NWnQc4FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fQOmlEPTB;MD6xPVk5PyEQvF2= NYDUe3p[W0GQR1XS
CP67-MEL NX3INGlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMkC0PFgh|ryP M1jjXHNCVkeHUh?=
DSH1 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW2VHRKSzVyPUCuNlQxODFizszN NFS3R2FUSU6JRWK=
HCE-4 NIHn[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ofGlEPTB;MD6yOlQ{QSEQvF2= MoDKV2FPT0WU
MZ2-MEL M3\3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDucXNKSzVyPUCuNlg2OzdizszN NETFdlJUSU6JRWK=
BL-41 NHroeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S1VGlEPTB;MD6yPVEzOyEQvF2= MmXaV2FPT0WU
HUTU-80 NGP2cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL3eJdKSzVyPUCuN|E1OiEQvF2= MmLUV2FPT0WU
LOXIMVI MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwM{G1NFMh|ryP M3;KcHNCVkeHUh?=
no-10 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwM{G5N|Eh|ryP NUPwWHZwW0GQR1XS
KARPAS-422 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTHTWM2OD1yLkOzPVk4KM7:TR?= NYLUfY9lW0GQR1XS
SW684 M{TmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfPTWM2OD1yLkO0PVgh|ryP NX33Z4x3W0GQR1XS
SF126 M3PPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwM{W0NUDPxE1? NIj0RWdUSU6JRWK=
D-263MG MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7VTWM2OD1yLkO2NlI1KM7:TR?= NVq4e2lkW0GQR1XS
OVCAR-4 NHjCe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwM{e0N|Mh|ryP M4[0W3NCVkeHUh?=
BB49-HNC NHLsOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T6NWlEPTB;MD6zPFU6QSEQvF2= NF;rfG9USU6JRWK=
ONS-76 M4HWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HleWlEPTB;MD60Nlk2OSEQvF2= NG\ubHNUSU6JRWK=
MZ7-mel MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnGZ4tPUUN3ME2wMlQ4QTFzIN88US=> M3fLV3NCVkeHUh?=
RCC10RGB MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvBVWpKSzVyPUCuOFkyOSEQvF2= M2i1c3NCVkeHUh?=
BOKU NFrTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjNUo9MUUN3ME2wMlQ6OTN|IN88US=> NXTjZZVtW0GQR1XS
no-11 NFK2dFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED2PHlKSzVyPUCuOVAzOjhizszN MXLTRW5ITVJ?
IST-SL2 NHPScpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG0U5RkUUN3ME2wMlUxOzB{IN88US=> NI[3OWdUSU6JRWK=
RKO NXTUfYJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXJb3A{UUN3ME2wMlUzQTZ4IN88US=> MlXtV2FPT0WU
HT-144 M1rYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTjSlN4UUN3ME2wMlU{PjB7IN88US=> NF;RSYZUSU6JRWK=
NCI-H446 M1;nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnnSpVKSzVyPUCuOlI4PiEQvF2= NWP0PYhoW0GQR1XS
QIMR-WIL Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iwcGlEPTB;MD63NFYzQSEQvF2= NWX3PGFLW0GQR1XS
MHH-PREB-1 M4HYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L5[WlEPTB;MD63OFQ3QSEQvF2= NYPWTmJGW0GQR1XS
EW-16 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnHU4tKSzVyPUCuO|YyPzhizszN MVLTRW5ITVJ?
EW-24 NHOyWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLTTWM2OD1yLke4NVY2KM7:TR?= M1HoV3NCVkeHUh?=
LB373-MEL-D NXPNdYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HyOWlEPTB;MD64NlUxQCEQvF2= MWrTRW5ITVJ?
TE-9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHKNXlKSzVyPUCuPFc2OzJizszN M2X4fHNCVkeHUh?=
A3-KAW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLkTWM2OD1yLkm4OFUzKM7:TR?= M2XTUXNCVkeHUh?=
A101D NWTTVGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwMEOwOFMh|ryP NHuyfGhUSU6JRWK=
OCUB-M MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XO[WlEPTB;MT6wOFQyOiEQvF2= M1nLTnNCVkeHUh?=
ES4 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK3Nm1SUUN3ME2xMlA2OTR3IN88US=> Mo\PV2FPT0WU
TE-6 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rIcGlEPTB;MT6yNVIzPiEQvF2= MkH4V2FPT0WU
D-502MG M{SzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwMkOzO|Yh|ryP NG\jfXNUSU6JRWK=
KNS-42 NUfxWGtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlruTWM2OD1zLkK0OFEzKM7:TR?= M1vwO3NCVkeHUh?=
SNU-C2B MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwM{C1PFkh|ryP NH7qTY1USU6JRWK=
NCI-H1838 NEjyXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXqTWM2OD1zLkOwO|M{KM7:TR?= MX\TRW5ITVJ?
NKM-1 NGX0dWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHKSY1vUUN3ME2xMlMxQDV7IN88US=> NFXyNodUSU6JRWK=
GI-1 M33JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\hTWM2OD1zLkO2NlIh|ryP NH7DeIZUSU6JRWK=
NB5 NEXxenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrNZJKSzVyPUGuN|k5OjdizszN NIrJZpFUSU6JRWK=
CAS-1 NX;DTGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXc2lEPTB;MT60NFk6OiEQvF2= NHnOOI1USU6JRWK=
HCE-T M{f1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwNU[3NVQh|ryP Ml7kV2FPT0WU
SBC-1 NVHaVmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrxOoF7UUN3ME2xMlU4QTh2IN88US=> MYDTRW5ITVJ?
JiyoyeP-2003 M2TTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoezTWM2OD1zLkezOFY3KM7:TR?= M4O1fnNCVkeHUh?=
TE-5 M1j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfRTWM2OD1zLke5NVM6KM7:TR?= NFTaSmFUSU6JRWK=
CAN MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwOEKyOVIh|ryP MXTTRW5ITVJ?
SK-UT-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3izeWlEPTB;Mj6xOlY6OyEQvF2= MV3TRW5ITVJ?
JVM-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TPNmlEPTB;Mj6zOlI5PCEQvF2= M1zsZ3NCVkeHUh?=
LB771-HNC Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3scFNKSzVyPUKuOVc2PTFizszN NG[wR4tUSU6JRWK=
NCCIT M1jhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zOZWlEPTB;Mj64OlYyPiEQvF2= NGPy[4tUSU6JRWK=
NCI-H2126 NVrP[WN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHWbItKSzVyPUKuPFc2PTJizszN M{S3e3NCVkeHUh?=
Calu-6 M1nO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jRb2lEPTB;Mz6wOVc1OSEQvF2= NULtZ|c1W0GQR1XS
SK-LMS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTNwMUG4PFYh|ryP MVTTRW5ITVJ?
ARH-77 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGToTpJKSzVyPUOuOFY6OTVizszN M1faWnNCVkeHUh?=
NB17 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRVXhKSzVyPUOuOlM5PDdizszN M3vaUHNCVkeHUh?=
A253 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwN{OyOFYh|ryP M3niVHNCVkeHUh?=
OPM-2 M2jER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrITWM2OD12LkK3Olg2KM7:TR?= NYfxbmJVW0GQR1XS
MV-4-11 NYDHUFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwM{[0OVQh|ryP NVm0OYdlW0GQR1XS
SR Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTRwNEm5OVQh|ryP M1rOZXNCVkeHUh?=
KG-1 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXZTWM2OD12Lk[wPFQ2KM7:TR?= Mn7oV2FPT0WU
OCI-AML2 NH;BN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTVwOE[xOVQh|ryP NYriOHVtW0GQR1XS
D-247MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjHO5ZKSzVyPU[uNVI2OTlizszN MYDTRW5ITVJ?
DJM-1 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HUeWlEPTB;Nj60PFU2QCEQvF2= MmPHV2FPT0WU
RPMI-6666 M4XZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTdwMkewOlch|ryP NXX1[4dvW0GQR1XS
KARPAS-45 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160Z2lEPTB;Nz61NVY4OSEQvF2= MXfTRW5ITVJ?
LP-1 NWi5WpZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwNUS3PFIh|ryP M{jXT3NCVkeHUh?=
RS4-11 NXf6e4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvGWG9KSzVyPUeuOlU4QDdizszN NX7tO5N[W0GQR1XS
DU-4475 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwWmlEPTB;OD6yNVY2OiEQvF2= M1jOfHNCVkeHUh?=
MONO-MAC-6 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRThwMkewOlYh|ryP M{LTRXNCVkeHUh?=
NCI-SNU-16 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRThwNU[xNlgh|ryP MUXTRW5ITVJ?
SJSA-1 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P5VGlEPTB;OD63NlgxPSEQvF2= MXPTRW5ITVJ?
MMAC-SF M2HuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRThwN{mzNFch|ryP NFHkboJUSU6JRWK=
SK-NEP-1 NVXOZWZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThwOEmxOVUh|ryP MYLTRW5ITVJ?
J-RT3-T3-5 NIfzcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRThwOU[1Nlkh|ryP M1y2dnNCVkeHUh?=
SKM-1 NYnXRVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTlwMEG3N|Qh|ryP M1nUR3NCVkeHUh?=
LB2241-RCC MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNPJJKSzVyPUmuNFIxOTJizszN NGnCR2NUSU6JRWK=
SIG-M5 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2TWM2OD17LkCyOFk{KM7:TR?= NHK1fplUSU6JRWK=
EVSA-T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTlwMke3PVMh|ryP MnfFV2FPT0WU
GT3TKB NFX4S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTlwM{W1OFYh|ryP NEfRfGtUSU6JRWK=
NB6 NF3qdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDGRYlKSzVyPUmuPVIzPTlizszN M4XrW3NCVkeHUh?=
EHEB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7yUG1xUUN3ME2xNE4xPjV4IN88US=> NEHE[JdUSU6JRWK=
HEL NInFeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TZPGlEPTB;MUCuOFc4PiEQvF2= M3fxOHNCVkeHUh?=
ALL-PO M{jVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILtWFJKSzVyPUGwMlc6OzhizszN NWjvT|hTW0GQR1XS
TGW NYjxdpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LXeWlEPTB;MUGuNlgzQCEQvF2= MnfyV2FPT0WU
BC-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TsTGlEPTB;MUKuNVE{QCEQvF2= MlfRV2FPT0WU
IA-LM M1XVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF{LkS0OFUh|ryP M{m1dnNCVkeHUh?=
UACC-257 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD3TWM2OD1zMj65NVk5KM7:TR?= MVfTRW5ITVJ?
KP-N-YS NX\YUI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\HTWM2OD1zMj65Nlg{KM7:TR?= NGfxeWFUSU6JRWK=
Raji Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF|Lke0PVch|ryP NWSwbJREW0GQR1XS
SF539 M{DoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD1zMz64OVU4KM7:TR?= NWDLUmk5W0GQR1XS
DMS-153 NHPVOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j6TWlEPTB;MUSuNFAzQCEQvF2= Ml64V2FPT0WU
L-540 M2PEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLqXplKSzVyPUG1MlA3PzJizszN M1yxW3NCVkeHUh?=
MN-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLWTWM2OD1zNT6xPVc6KM7:TR?= MnXHV2FPT0WU
RPMI-8866 M1v0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vQUmlEPTB;MUeuOFQ2PCEQvF2= NXHxeFNXW0GQR1XS
NCI-H510A NYDTN4Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTob2hbUUN3ME2xPU4{QTd|IN88US=> NGfHXFJUSU6JRWK=
NB13 M3znSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ETIRKSzVyPUG5MlQ5PzdizszN M2TJe3NCVkeHUh?=
HAL-01 NXjieG13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnFZYN3UUN3ME2xPU44PTR|IN88US=> MV;TRW5ITVJ?
NCI-H720 NIPqfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XQPGlEPTB;MkCuNlc{OyEQvF2= M1Hqc3NCVkeHUh?=
REH MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\xTWM2OD1{MD62N|U4KM7:TR?= MlnSV2FPT0WU
KNS-81-FD NIHDVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W1N2lEPTB;MkOuNVQ3KM7:TR?= MV3TRW5ITVJ?
HC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K5cGlEPTB;MkSuOVU2OSEQvF2= NX\TPHR5W0GQR1XS
NCI-H2141 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ2Lke3OVQh|ryP M3;zSHNCVkeHUh?=
MOLT-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3aTWM2OD1{Nj62O|U{KM7:TR?= Mnn3V2FPT0WU
OMC-1 NEG4S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\HNGNnUUN3ME2yO{4yPDJ{IN88US=> M3;GVnNCVkeHUh?=
LC-1F MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjFNGZKSzVyPUK3MlMzPDVizszN M2m5T3NCVkeHUh?=
NCI-H1304 NIPPTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PvbWlEPTB;MkiuNVYzQCEQvF2= NXzTTWRuW0GQR1XS
BC-1 NWnLNZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ6Lk[1NUDPxE1? NWWxZ2tDW0GQR1XS
NCI-H64 NHXBRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ7Lk[yOVMh|ryP NEL1cVlUSU6JRWK=
MOLT-16 M3W2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3aUG9VUUN3ME2yPU43Ojl{IN88US=> NEKxbo1USU6JRWK=
U-87-MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNyLke2OkDPxE1? NE\4OlBUSU6JRWK=
GAK M3nDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNzLkK2PFYh|ryP NGP3NIpUSU6JRWK=
ES8 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN{LkGyOVIh|ryP M{n4UXNCVkeHUh?=
HCC1599 M{Du[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jyZWlEPTB;M{KuN|MzPSEQvF2= NYn6cGNrW0GQR1XS
EB-3 NWT5XFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN2LkOxNVch|ryP NFrMO3FUSU6JRWK=
HCC1187 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmxTWM2OD1|NT64NFUzKM7:TR?= MYXTRW5ITVJ?
SK-PN-DW MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnQRYw2UUN3ME2zOk4yQTR|IN88US=> MVvTRW5ITVJ?
JVM-3 M1zjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPpW4xKSzVyPUO3MlI{OzhizszN M17NUXNCVkeHUh?=
HCC2157 NIXkN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G5NWlEPTB;M{euPVk1PiEQvF2= MXfTRW5ITVJ?
A4-Fuk M4[1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTN6LkGwNFkh|ryP M{LLUHNCVkeHUh?=
COR-L279 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRyLkK4OVEh|ryP NFrxUZlUSU6JRWK=
DEL NES2[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXIclhVUUN3ME20NU46ODh4IN88US=> MWLTRW5ITVJ?
NCI-H1395 NHnKWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXThW3RrUUN3ME20Nk4xOTZ|IN88US=> NHfvfYpUSU6JRWK=
MHH-NB-11 NEjRdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT0PW81UUN3ME20N{4xQDF6IN88US=> M{nEZnNCVkeHUh?=
NCI-H2107 NY\pflRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPSTWM2OD12Mz60PFQ3KM7:TR?= M1rZV3NCVkeHUh?=
NEC8 NGj5WFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\0TWM2OD12ND6zN|Yh|ryP NHTLSVJUSU6JRWK=
COLO-684 M1vsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjpTWM2OD12Nj6yNlU5KM7:TR?= NV3sT5JoW0GQR1XS
LS-411N MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvieGd5UUN3ME20PE41PzR6IN88US=> MVnTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
細胞試験:

[1]

+ 展開
  • 細胞株: Ba/F3 cell lines
  • 濃度: ~32 nM
  • 反応時間: 72 hours
  • 実験の流れ:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • 製剤: DMSO
  • 投薬量: 30 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管
in solvent
別名 BMS-354825

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 問題2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src信号経路図

Src Inhibitors with Unique Features

相関Src製品

Tags: Dasatinibを買う | Dasatinib ic50 | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib化学構造 | Dasatinib分子量 | Dasatinib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID